Tampa, Florida, U.S., September 22, 2026
Tampa General Hospital has become the first academic health system in the Southeast to adopt innovative host-response technology designed to support earlier and more precise assessment of patients with suspected sepsis. The initiative introduces a molecular diagnostic approach intended to help clinicians better understand how an individual patient’s immune system is responding to infection and distinguish different biological responses that can influence treatment decisions. By incorporating advanced host-response information into clinical care, Tampa General aims to strengthen sepsis recognition, risk assessment and personalized treatment, while supporting its broader commitment to precision medicine and advanced diagnostic technologies.
Host-Response Technology Supports Sepsis Assessment
Sepsis is a life-threatening medical condition that occurs when the body’s response to infection causes organ dysfunction. Rapid identification and appropriate treatment are critical because patients can deteriorate quickly, while the biological response to infection can vary substantially between individuals. Traditional approaches often rely on clinical signs, laboratory measurements and microbiological testing, but these methods may not fully capture the patient’s underlying immune response. The newly adopted host-response technology is designed to provide additional biological information by examining molecular signals associated with the body’s response to infection. Rather than focusing solely on identifying the infectious organism, host-response testing evaluates the patient’s own immune response.
This approach may help clinicians obtain a more comprehensive picture of the patient’s condition and support more informed decisions as treatment progresses. Tampa General said the technology will complement existing clinical evaluation and is intended to provide actionable information for physicians treating patients with suspected sepsis. The adoption represents an effort to integrate advanced molecular diagnostics into real-world hospital care, potentially improving the speed and precision of clinical decision-making.
Advancing Precision Medicine in Sepsis Care
Advertisement
The implementation of host-response technology reflects the growing role of precision medicine in acute-care settings. Sepsis is biologically complex, and patients with apparently similar clinical presentations may have substantially different immune responses. Understanding those differences could help clinicians better categorize patients according to their biological risk and response patterns. Tampa General’s adoption of the technology also highlights the increasing convergence of molecular diagnostics, data-driven medicine and clinical care. Host-response information can potentially add another layer to conventional diagnostic testing by providing insight into the patient’s biological state.
This could be particularly valuable in situations where clinicians must make rapid treatment decisions before conventional laboratory or microbiological results are available. As an academic health system, Tampa General also has a role in evaluating and advancing emerging healthcare technologies. The implementation provides an opportunity to incorporate innovative diagnostics into clinical workflows while generating practical experience with their use in a large healthcare environment. Such adoption can contribute to broader understanding of how molecular testing can support evidence-based and individualized patient management.
Tampa General Strengthens Advanced Diagnostic Capabilities
The new technology forms part of Tampa General’s broader efforts to advance innovative healthcare and precision medicine. The hospital system has increasingly focused on technologies that can improve diagnosis, treatment and patient outcomes while supporting research and clinical education. For sepsis care, the ability to characterize a patient’s host response could potentially complement established diagnostic approaches and help clinicians identify patients who require more intensive monitoring or intervention. However, host-response testing should be viewed as an additional clinical tool, rather than a replacement for physician assessment, microbiological testing or established sepsis-management protocols.
The adoption is also significant from a healthcare-technology perspective because Tampa General is the first academic health system in the Southeast to implement the technology. Academic medical centers can play an important role in evaluating emerging diagnostics and determining how they can be integrated into routine clinical practice. The broader development of host-response diagnostics reflects an important shift in infectious-disease medicine. Instead of relying exclusively on pathogen identification, researchers and clinicians are increasingly examining how the human body responds to infection. This approach could support more individualized assessment of complex conditions such as sepsis, where immune responses and disease progression can vary considerably between patients. Tampa General’s adoption therefore represents a notable step toward incorporating molecular host-response information into sepsis care. As clinical experience grows, further research will be important to determine how the technology affects treatment decisions, clinical outcomes and healthcare workflows. The initiative nevertheless demonstrates the expanding role of advanced diagnostics and precision medicine in addressing one of the most urgent challenges in acute healthcare.
Source: Tampa General Hospital press release
